Division of Cardiovascular Diseases and Hypertension

Program Description:

The Advanced Cardiac Imaging Fellowship Program is a 12-month program that provides hands-on supervised clinical training, research, formal didactics, and multi-imaging conferences (Cardiovascular CT, Cardiovascular MRI, Nuclear Cardiology, Cardiac PET) provided to the Fellow/trainee under the direct supervision of the Program Director and/or the Chief of the Division of Cardiology, Robert Wood Johnson Medical School (RWJMS) and Robert Wood Johnson University Hospital (RWJUH).

Modalities:

• Cardiovascular CT

• Cardiovascular MRI

• Nuclear Cardiology

• Cardiac PET

Duration:

1 year (Starting July 1, 2026)

Number of Trainees Accepted Yearly:

2

How to Apply:

Interested candidates should send their CV and cover letter addressed to the Program Director, Dr. Sabahat Bokhari to: advanced-imaging@rwjms.rutgers.edu.

Application deadline: September 20, 2025.

Shortlisted applicants will be invited to interview with the Program Director and select faculty in October.

Program Description:

The Advanced Heart Failure/Heart Transplant/Mechanical Circulatory Support (MCS) Fellowship Program is a 12-month non-ACGME-accredited program offering training in Advanced Heart Failure, Heart Transplantation, and Mechanical Circulatory Support. The program provides comprehensive training in heart failure, cardiomyopathies, transplant, and LVAD, with the time divided between inpatient and outpatient services. The fellows will participate in our expanding cardiogenic shock program. Electives are available in cardiac amyloidosis and cardio-oncology. Strong research interest is encouraged.

Duration:

1 year (Starting July 1, 2026)

Number of Trainees per year:

2

How to Apply:

Interested candidates should send their CV and cover letter addressed to the Program Director, Maya Guglin, MD, PHD, FACC to: advanced-HF@rwjms.rutgers.edu.

Application deadline: September 20, 2025.

Shortlisted applicants will be invited to interview with the Program Director.

ACE @ RWJMS & RWJUH

Robert Wood Johnson University Hospital (RWJUH) and Rutgers Robert Wood Johnson Medical School (RWJMS) have established the Amyloid Center of excellence to diagnose patients with rare, but potentially fatal, amyloid conditions earlier and treat them more effectively through personalized medicine.

Patients in the Amyloidosis Center at RWJUH and Rutgers RWJMS benefit from a multidisciplinary team approach that includes specialists across a broad range of disciplines such as heart and vascular care, neurology, hematology, nephrology, pathology and bone marrow transplantation. The clinical teams work together to identify the forms of the disease and develop an effective, individualized treatment plan.

Sabahat Bokhari, MD, an internationally recognized amyloidosis expert, serves as director of the center, the first program of its kind in New Jersey. Dr. Bokhari has made significant contributions to the proper diagnosis of amyloidosis. He pioneered the development of a noninvasive imaging method called technetium-99m pyrophosphate scintigraphy (PYP) imaging, which is used worldwide and is recommended by professional medical organizations such as the American College of Cardiology, the American Heart Association, and the American Society of Nuclear Cardiology for evaluating a form of the disease called cardiac transthyretin amyloidosis. 

Learn More About the Amyloidosis Center

Amyloidosis is a rare, progressive, debilitating and fatal disease that happens when abnormal proteins build up in different organs, like the heart, kidneys, liver, and nerves. This buildup can make it hard for these organs to work properly and may lead to serious health problems if not treated.

There are 42 proteins that cause amyloidosis, and it is essential to confirm the diagnosis of amyloid and the specific subtype to determine the optimal treatment approach. 

The two most common are: 

• AL (Light Chain) Amyloidosis – caused by abnormal cells in the bone marrow and linked to multiple myeloma (a type of blood cancer). 

• Transthyretin (ATTR) Amyloidosis – caused by too much of a protein called transthyretin (TTR), made by the liver. ATTR has two causes: the first is unknown but associated with aging, and the second is due to genetic variants. Over 150 genetic mutations have been identified within the TTR gene, which are associated with amyloidosis. Some forms of ATTR are inherited, so family members may need to be tested.

Doctors treat amyloidosis based on the type and which organs are affected. Specialists in blood disorders, heart health, and nerve diseases work together to help manage the condition. While amyloidosis can be serious, treatments are available to improve symptoms and prevent complications. 

Diagnosing amyloidosis requires a combination of laboratory tests, imaging techniques, and/or tissue biopsies to confirm amyloid deposition and determine its subtype. 

A thorough and precise diagnosis is essential to guide the appropriate treatment approach for each patient. 

To schedule an appointment, please call 1-866-NJAMYLOID / 1-866-652-6956

HCMCE @ RWJMS & RWJUH

The Hypertrophic Cardiomyopathy (HCM) Center of Excellence at Robert Wood Johnson University Hospital, part of Rutgers Robert Wood Johnson Medical School, is a comprehensive initiative dedicated to the diagnosis, treatment, and long-term management of hypertrophic cardiomyopathy. Established in November 2022, HCMCE integrates advanced imaging, genetic evaluation, innovative therapies, and a collaborative multidisciplinary approach. Anchored within New Jersey’s largest academic health system, it serves patients and families across central New Jersey, southern New Jersey, and the surrounding regions. With experienced leadership, a growing referral network, and an expanding research portfolio, the program is positioned to become the premier destination for HCM care in the state.

Hypertrophic Cardiomyopathy (HCM) is a multifaceted genetic heart disorder characterized by abnormal thickening of the heart muscle, which can obstruct blood flow and lead to symptoms such as chest pain, shortness of breath, fatigue, and irregular heart rhythms. HCM affects about 1 in 500 people but is often underdiagnosed, with only around 100,000 individuals in the U.S. currently receiving treatment. Although not rare, HCM is frequently overlooked and underdiagnosed. Since it is inherited, early detection and family screening are essential for effective management. Without proper treatment, HCM can lead to serious complications, including sudden cardiac death. HCM is also the leading cause of sudden cardiac death in athletes, making awareness and screening especially critical for athletic communities such as Rutgers. At our clinic, we utilize advanced diagnostics, personalized therapies, and interventional procedures when necessary to improve heart function and reduce risks.

The HCM Program provides comprehensive, patient-centered services, including:

Initial Evaluation

• Detailed medical history and physical exam
• Electrocardiography (ECG)
• Echocardiogram
• Heart rhythm monitoring

Advanced Imaging

• Resting and stress echocardiography
• Cardiac MRI
• Cardiac CT
• Positron Emission Tomography (PET)

Genetic Counseling & Testing

• Risk assessment for first-degree relatives
• Family screening for inherited cardiomyopathy
• Pre and Post Genetic Test Counseling
• Long-term guidance and support

Medical & Interventional Therapies

• Medication management, including Camzyos and Norpace
• Septal myectomy
• Alcohol septal ablation
• Implantable cardioverter-defibrillators (ICDs)
• Permanent Pacemakers

Outpatient Clinic

• Appointments at the new Ambulatory Medical Pavilion
• On-site ECG, Echocardiogram, MRI, PET, CT, and stress testing
• Seamless coordination with pediatric cardiology, electrophysiology, advanced heart failure, and cardiac surgery teams

Research

Our clinic is deeply committed to advancing the understanding and treatment of hypertrophic cardiomyopathy through active involvement in multiple clinical trials. These include NIH-sponsored studies as well as industry-funded research focused on “big heart” conditions. By participating in these cutting-edge trials, we contribute to the development of innovative therapies and improved patient outcomes. This commitment ensures that our patients have access to the latest advances in HCM care and that we remain at the forefront of evolving treatment options.

Learn More about Dr. Bokhari's Publications

Education

We are equally dedicated to educating and training the next generation of HCM specialists. Our Amyloid/HCM fellowship program provides a comprehensive and immersive learning experience. The program is directed by our clinic director, who serves as the fellowship program director. Fellows benefit from hands-on exposure to complex cases, multidisciplinary collaboration, and involvement in pioneering research at a recognized center of excellence. Through this fellowship, trainees gain the clinical expertise and research skills necessary to become future leaders in the diagnosis, management, and treatment of hypertrophic cardiomyopathy and cardiac amyloidosis.

Location:

Ambulatory Medical Pavilion
210 Somerset Street, 8^th Floor
New Brunswick, NJ 08901

Parking:

Valet Parking available.

Covered parking is also available at New Brunswick Parking Authority deck at 50 Plum Street. Exit the lower level (LL) of the parking garage onto Plum Street or Prospect Street and proceed towards Somerset Street to the main lobby entrance. Please bring your parking ticket in to the office so we can provide a validated discount.

To schedule an appointment, please call (732) 235-6561.